# US 2022/0031653 A1 · Compounds for Treating Tauopathies and Restless Leg Syndrome and Methods of Using and Screening for Same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031653 A1
- Document ID: US20220031653A1
- Status: Published application
- Kind: A1
- Application number: 17/390,497
- Filed: 2021-07-30
- Published: 2022-02-03
- Earliest claimed: 2020-07-30
- Applicants: United States Government as Represented by the Department of Veterans Affairs
- Inventors: George Richard Uhl; Ian M. Henderson
- Web page: https://patentgrep.com/patent/US20220031653A1

## CPC

- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- C12Q 1/42: involving phosphatase
- G01N 2333/91205: Phosphotransferases in general
- G01N 2500/02: Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided are compounds capable of enhancing the ability of receptor-type tyrosine-protein phosphatase delta (PTPRD) to dephosphorylate a kinase. Also disclosed is a method of treating a tauopathy or restless leg syndrome in a subject comprising administering to the subject an effective amount of a disclosed compound. Also disclosed are kits comprising the compounds together with instructions for treating a condition and/or a compound known for treating the condition. Finally, disclosed herein is a screening method suitable for identifying positive allosteric modulators of the ability of a receptor-type tyrosine-protein phosphatase delta (PTPRD) to dephosphorylate a kinase.

## Claims

### Claim 1

A method of treating a tauopathy or restless leg syndrome in a subject, comprising administering to the subject an effective amount of a compound represented by Formula (I):
or a pharmaceutically acceptable salt thereof; wherein R1 is hydrogen or —CH3; R2, R3, and R5 are each independently hydrogen or —OH; and R4 is hydrogen, —OH, or —OCH3.

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound is:

### Claim 3 (depends on 1)

The method of claim 1, wherein the compound is Quercetin.

### Claim 4 (depends on 1)

The method of claim 1, wherein the tauopathy is Alzheimer's disease, chronic traumatic encephalopathy, corticobasal degeneration, frontotemporal lobar degeneration, behavioral variant frontotemporal dementia, language variant frontotemporal dementia, right temporal variant frontotemporal dementia, Pick disease, or progressive supranuclear palsy.

### Claim 5 (depends on 1)

The method of claim 1, further comprising administering to the subject an effective amount of a compound known for treating the tauopathy or restless leg syndrome.

### Claim 6

A method of enhancing the ability of receptor-type tyrosine-protein phosphatase delta (PTPRD) to dephosphorylate a kinase, the method comprising contacting PTPRD with an effective amount of a compound represented by Formula (I):
or a pharmaceutically acceptable salt thereof; wherein R1 is hydrogen or —CH3; R2, R3, and R5 are each independently hydrogen or —OH; and R4 is hydrogen, —OH, or —OCH3.

### Claim 7 (depends on 6)

The method of claim 6, wherein the compound is:

### Claim 8 (depends on 6)

The method of claim 6, wherein the compound is Quercetin.

### Claim 9 (depends on 6)

The method of claim 6, wherein the kinase is glycogen synthase kinase GSK3β, glycogen synthase kinase GSK3α, cyclin dependent kinase-5 CDK5, or a combination thereof.

### Claim 10

A kit comprising:
a) a compound represented by Formula (I) in an amount effective for treating a tauopathy or restless leg syndrome in a subject,
or a pharmaceutically acceptable salt thereof; wherein R1 is hydrogen or —CH3; R2, R3, and R5 are each independently hydrogen or —OH; and R4 is hydrogen, —OH, or —OCH3; and
b) instructions for treating the tauopathy or restless leg syndrome and/or an effective amount of a compound known for treating the tauopathy or restless leg syndrome.

### Claim 11 (depends on 10)

The kit of claim 10, wherein the compound represented by Formula (I) is:

### Claim 12 (depends on 10)

The kit of claim 10, wherein the compound represented by Formula (I) is Quercetin.

### Claim 13 (depends on 10)

The kit of claim 10, wherein the tauopathy is Alzheimer's disease, chronic traumatic encephalopathy, corticobasal degeneration, frontotemporal lobar degeneration, behavioral variant frontotemporal dementia, language variant frontotemporal dementia, right temporal variant frontotemporal dementia, Pick disease, or progressive supranuclear palsy.

### Claim 14 (depends on 10)

The kit of claim 10, wherein the effective amount of the compound of Formula (I) and/or the compound known for treating the tauopathy or restless leg syndrome is a therapeutically effective amount.

### Claim 15 (depends on 10)

The kit of claim 10, wherein the effective amount of the compound of Formula (I) and/or the compound known for treating the tauopathy or restless leg syndrome is a prophylactically effective amount.

### Claim 16

A method of screening for positive allosteric modulators of the ability of a receptor-type tyrosine-protein phosphatase delta (PTPRD) to dephosphorylate a kinase, the method comprising:
a) contacting the PTPRD with a test compound in the presence of the phosphorylated kinase; and
b) measuring any orthophosphate release from the kinase;
wherein the PTPRD comprises a phosphatase D1 domain having at least 80% amino acid identity with SEQ ID NO: 1; and
wherein the kinase is GSKα or GSKβ comprising a polypeptide having at least 80% amino acid identity with SEQ ID NO: 2 or CDK5 comprising a polypeptide having at least 80% amino acid identity with SEQ ID NO: 4.

### Claim 17 (depends on 16)

The method of claim 16, wherein the phosphatase D1 domain is SEQ ID NO: 1.

### Claim 18 (depends on 16)

The method of claim 16, wherein the kinase is GSKα or GSKβ comprising a polypeptide having SEQ ID NO: 2 or CDK5 comprising a polypeptide having SEQ ID NO: 4.

### Claim 19 (depends on 16)

The method of claim 16, wherein the test compound is a flavanoid.

### Claim 20 (depends on 16)

The method of claim 16, wherein the test compound is a flavanol.
